Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

In this small study involving older adults, adverse events associated with the mRNA-1273 vaccine were mainly mild or moderate. The 100-μg dose induced higher binding- and neutralizing-antibody titers than the 25-μg dose, which supports the use of the 100-μg dose in a phase 3 vaccine trial.

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Size: 749 KB